Anti‐leukaemic effects induced by APR‐246 are dependent on induction of oxidative stress and the NFE2L2/HMOX1 axis that can be targeted by PI3K and mTOR inhibitors in acute myeloid leukaemia cells

In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2

Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · see citing works

An Nrf2/Small Maf Heterodimer Mediates the Induction of Phase II Detoxifying Enzyme Genes through Antioxidant Response Elements

Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999 · see citing works

The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53

Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995 · see citing works

Requirement for p53 and p21 to Sustain G ₂ Arrest After DNA Damage

Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J. P., Sedivy, J. M., Kinzler, K. W., & Vogelstein, B. (1998) · Science · doi:10.1126/science.282.5393.1497 · Cited by 2,803 · see citing works

TP53 mutations in human cancers: origins, consequences, and clinical use.

Olivier, M., Hollstein, M., & Hainaut, P. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001008 · Cited by 2,199 · see citing works

Nrf2–Keap1 defines a physiologically important stress response mechanism

Motohashi, H., & Yamamoto, M. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.09.003 · Cited by 1,725 · see citing works

Nrf2 signaling in coordinated activation of antioxidant gene expression

Jaiswal, A. K. (2004) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2004.02.074 · Cited by 1,254 · see citing works

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound

Bykov, V. J. N., Issaeva, N., Shilov, A., Hultcrantz, M., Pugacheva, E., Chumakov, P., Bergman, J., Wiman, K. G., & Selivanova, G. (2002) · Nature Medicine · doi:10.1038/nm0302-282 · Cited by 1,067 · see citing works

Regulation of PTEN Transcription by p53

Stambolic, V., MacPherson, D. P., Sas, D., Lin, Y., Snow, B., Jang, Y., Benchimol, S., & Mak, T. W. (2001) · Molecular Cell · doi:10.1016/s1097-2765(01)00323-9 · Cited by 913 · see citing works

TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes

Petitjean, A., Achatz, M. I. W., Borresen-Dale, A. L., Hainaut, P., & Olivier, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210302 · Cited by 884 · see citing works

Current Protocols in Cytometry

(2001) · John Wiley & Sons, Inc. eBooks · doi:10.1002/0471142956 · Cited by 869 · see citing works

Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors

Issaeva, N., Bozko, P. M., Enge, M., Protopopova, M., Verhoef, L. G. G. C., Masucci, M. G., Pramanik, A., & Selivanova, G. (2004) · Nature Medicine · doi:10.1038/nm1146 · Cited by 749 · see citing works

TP53 Mutation and Survival in Chronic Lymphocytic Leukemia

Zenz, T., Eichhorst, B. F., Busch, R. M., Denzel, T., Häbe, S., Winkler, D. F. H., Bühler, A., Edelmann, J., Bergmann, M., Hopfinger, G., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.8762 · Cited by 617 · see citing works

p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies

Wattel, E., Preudhomme, C., Hecquet, B., Vanrumbeke, M., Quesnel, B., Dervite, I., Morel, P., & Fenaux, P. (1994) · Blood · doi:10.1182/blood.v84.9.3148.3148 · Cited by 592 · see citing works

PRIMA-1 reactivates mutant p53 by covalent binding to the core domain

Lambert, J. M. R., Gorzov, P., Veprintsev, D. B., Söderqvist, M., Segerbäck, D., Bergman, J., Fersht, A. R., Hainaut, P., Wiman, K. G., & Bykov, V. J. N. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.03.003 · Cited by 592 · see citing works

Anticancer Activity of Metal Complexes: Involvement of Redox Processes

Jungwirth, U., Kowol, C. R., Keppler, B. K., Hartinger, C. G., Berger, W., & Heffeter, P. (2011) · Antioxidants and Redox Signaling · doi:10.1089/ars.2010.3663 · Cited by 559 · see citing works

Heme oxygenase/carbon monoxide signaling pathways: Regulation and functional significance

Ryter, S. W., Otterbein, L. E., Morse, D., & Choi, A. M. K. (2002) · Molecular and Cellular Biochemistry · doi:10.1023/a:1015957026924 · Cited by 497 · see citing works

Regulation of p53 stability

Ashcroft, M. A., & Vousden, K. H. (1999) · Oncogene · doi:10.1038/sj.onc.1203012 · Cited by 407 · see citing works

Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer

Lehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406 · see citing works

PTEN Protects p53 from Mdm2 and Sensitizes Cancer Cells to Chemotherapy

Mayo, L. D., Dixon, J. E., Durden, D. L., Tonks, N. K., & Donner, D. B. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m108302200 · Cited by 351 · see citing works

General, Applied and Systems Toxicology

(2009) · Wiley eBooks · doi:10.1002/9780470744307 · Cited by 342 · see citing works

PI3K is a key molecule in the Nrf2‐mediated regulation of antioxidative proteins by hemin in human neuroblastoma cells

Nakaso, K., Yano, H., Fukuhara, Y., Takeshima, T., Wada‐Isoe, K., & Nakashima, K. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00517-9 · Cited by 324 · see citing works

Functional characterization and role of INrf2 in antioxidant response element-mediated expression and antioxidant induction of NAD(P)H:quinone oxidoreductase1 gene

Dhakshinamoorthy, S., & Jaiswal, A. K. (2001) · Oncogene · doi:10.1038/sj.onc.1204506 · Cited by 290 · see citing works

The role of glutathione in the transport and catabolism of nitric oxide

Hogg, N., Singh, R., & Kalyanaraman, B. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)00086-5 · Cited by 274 · see citing works

PRIMA-1MET synergizes with cisplatin to induce tumor cell apoptosis

Bykov, V. J. N., Zache, N., Stridh, H., Westman, J., Bergman, J., Selivanova, G., & Wiman, K. G. (2005) · Oncogene · doi:10.1038/sj.onc.1208419 · Cited by 252 · see citing works

Mechanism of p53 stabilization by ATM after DNA damage

Cheng, Q., & Chen, J. (2010) · Cell Cycle · doi:10.4161/cc.9.3.10556 · Cited by 248 · see citing works

Bioluminescence of cellular ATP: a new method for evaluating cytotoxic agents in vitro.

Kangas, L., Grönroos, M. A., & Nieminen, A. L. (1984) · PubMed · Cited by 221 · see citing works

Cellular Redox Pathways as a Therapeutic Target in the Treatment of Cancer

Montero, A. J., & Jassem, J. (2011) · Drugs · doi:10.2165/11592590-000000000-00000 · Cited by 194 · see citing works

Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3

Patton, J. T., Mayo, L. D., Singhi, A. D., Gudkov, A. V., Stark, G. R., & Jackson, M. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3832 · Cited by 189 · see citing works

Acute myeloid leukemia with a complex aberrant karyotype is a distinct biological entity characterized by genomic imbalances and a specific gene expression profile

Schoch, C., Kern, W., Kohlmann, A., Hiddemann, W., Schnittger, S., & Haferlach, T. (2005) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20193 · Cited by 188 · see citing works

APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase

Peng, X., Zhang, M.-Q.-Z., Conserva, F., Hosny, G., Selivanova, G., Bykov, V. J. N., Arnér, E. S. J., & Wiman, K. G. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.417 · Cited by 170 · see citing works

PRIMA-1Met induces myeloma cell death independent of p53 by impairing the GSH/ROS balance

Tessoulin, B., Descamps, G., Moreau, P., Maïga, S., Lodé, L., Godon, C., Marionneau-Lambot, S., Oullier, T., Le Gouill, S., Amiot, M., et al. (2014) · Blood · doi:10.1182/blood-2014-01-548800 · Cited by 166 · see citing works

Pharmacological reactivation of mutant p53: from protein structure to the cancer patient

Wiman, K. G. (2010) · Oncogene · doi:10.1038/onc.2010.188 · Cited by 140 · see citing works

Phosphoinositide 3-OH Kinase (PI3K) and PKB/Akt Delay the Onset of p53-mediated, Transcriptionally Dependent Apoptosis

Sabbatini, P., & McCormick, F. P. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.34.24263 · Cited by 139 · see citing works

4-Ketopinoresinol, a novel naturally occurring ARE activator, induces the Nrf2/HO-1 axis and protects against oxidative stress-induced cell injury via activation of PI3K/AKT signaling

Chen, H., Chen, Y.-T., Huang, Y.-W., Tsai, H., & Kuo, C. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.12.012 · Cited by 133 · see citing works

Restoration of p53 Pathway by Nutlin-3 Induces Cell Cycle Arrest and Apoptosis in Human Rhabdomyosarcoma Cells

Miyachi, M., Kakazu, N., Yagyu, S., Katsumi, Y., Tsubai-Shimizu, S., Kikuchi, K., Tsuchiya, K., Iehara, T., & Hosoi, H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2955 · Cited by 101 · see citing works

TP53 mutations in myeloid malignancies are either homozygous or hemizygous due to copy number-neutral loss of heterozygosity or deletion of 17p

Jasek, M., Gondek, L. P., Bejanyan, N., Tiu, R. V., Huh, J. Y., Theil, K. S., O'Keefe, C., McDevitt, M. A., & Maciejewski, J. P. (2009) · Leukemia · doi:10.1038/leu.2009.189 · Cited by 83 · see citing works

APR-246 exhibits anti-leukemic activity and synergism with conventional chemotherapeutic drugs in acute myeloid leukemia cells

Ali, D., Jönsson‐Videsäter, K., Deneberg, S., Bengtzén, S., Nahi, H., Paul, C., & Lehmann, S. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01557.x · Cited by 70 · see citing works

The N-terminal conformation of Bax regulates cell commitment to apoptosis

Upton, J.-P., Valentijn, A., Zhang, L., & Gilmore, A. P. (2007) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4402092 · Cited by 57 · see citing works

Efficient, high-throughput transfection of human embryonic stem cells

Moore, J. C., Atze, K., Yeung, P. L., et al. (2010) · Stem Cell Research & Therapy · doi:10.1186/scrt23 · Cited by 52 · see citing works

Investigation of the role of p53 in chemotherapy resistance of lung cancer cell lines.

Breen, L., Heenan, M., Murphy, V., & CLYNES, M. M. (2007) · PubMed · Cited by 44 · see citing works

FRET imaging and statistical signal processing reveal positive and negative feedback loops regulating the morphology of randomly migrating HT-1080 cells.

Kunida, K., Matsuda, M., & Aoki, K. (2012) · Journal of Cell Science · doi:10.1242/jcs.096859 · Cited by 35 · see citing works

In vitro chemosensitivity testing in acute non lymphocytic leukemia using the bioluminescence ATP assay

Möllgård, L., Tidefelt, U., Sundman‐Engberg, B., Löfgren, C., & Paul, C. (2000) · Leukemia Research · doi:10.1016/s0145-2126(00)00003-5 · Cited by 32 · see citing works

KBM-3, an in vitro model of human acute myelomonocytic leukemia.

Andersson, B. S., Bergerheim, U. S. R., Collins, V. P., Childs, C. C., Beran, M., Sen, S., Arden, K. C., Pathak, S., Siciliano, M. J., & Ost, A. (1992) · PubMed · Cited by 19 · see citing works

Targeting p53 pathways: mechanisms, structures, and advances in therapy

Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016 · see citing works

Targeting mutant p53 for efficient cancer therapy

Bykov, V. J. N., Eriksson, S. E., Bianchi, J., & Wiman, K. G. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.109 · Cited by 889 · see citing works

Synergistic effects of PRIMA-1^Met (APR-246) and 5-azacitidine in <i>TP53</i>-mutated myelodysplastic syndromes and acute myeloid leukemia

Maslah, N., Salomao, N., Drevon, L., Verger, E., Partouche, N., Ly, P., Aubin, P., Naoui, N., Schlageter, M.-H., Bally, C., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.218453 · Cited by 132 · see citing works

PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies

Perdrix, A., Najem, A., Saussez, S., Awada, A., Journe, F., Ghanem, G., & Krayem, M. (2017) · Cancers · doi:10.3390/cancers9120172 · Cited by 126 · see citing works

Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction

Fujihara, K. M., Zhang, B. Z., Jackson, T. D., Ogunkola, M. O., Nijagal, B., Milne, J. V., Sallman, D. A., Ang, C.-S., Nikolic, I., Kearney, C. J., et al. (2022) · Science Advances · doi:10.1126/sciadv.abm9427 · Cited by 103 · see citing works

A thiol-bound drug reservoir enhances APR-246-induced mutant p53 tumor cell death

Ceder, S., Eriksson, S. E., Cheteh, E. H., Dawar, S., Corrales Benitez, M., Bykov, V. J. N., Fujihara, K. M., Grandin, M., Li, X., Ramm, S., et al. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.201910852 · Cited by 41 · see citing works

The Mutant p53-Targeting Compound APR-246 Induces ROS-Modulating Genes in Breast Cancer Cells

Synnott, N. C., Madden, S. F., Bykov, V. J. N., Crown, J., Wiman, K. G., & Duffy, M. J. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.08.009 · Cited by 35 · see citing works

Altered Expression of Heme Oxygenase 2 in Heme Oxygenase 1–deficient Mouse Embryos

Rana, M., Bajaj, D., Choubey, P., Jain, S., & Modak, S. B. (2023) · Journal of Histochemistry & Cytochemistry · doi:10.1369/00221554231189310 · Cited by 6 · see citing works

Heme oxygenase decycling 1 (HMOX1; HO-1; Hsp32)

(2012) · Science-Business eXchange · doi:10.1038/scibx.2012.19

Heme Oxygenase-1: An Anti-Inflammatory Effector in Cardiovascular, Lung, and Related Metabolic Disorders

Ryter, S. W. (2022) · Antioxidants · doi:10.3390/antiox11030555 · Cited by 281 · see citing works

Characterization of heme oxygenase and biliverdin reductase gene expression in zebrafish (Danio rerio): Basal expression and response to pro-oxidant exposures

Holowiecki, A., O'Shields, B., & Jenny, M. J. (2016) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2016.09.022 · Cited by 22 · see citing works

Effect of natural and semisynthetic flavonoids on the expression of heme oxygenase-1

Ulrichová, J., Vrba, J., Weiszenstein, M., et al. (2012) · Planta Medica · doi:10.1055/s-0032-1321143